By Colin Kellaher
Kenvue has struck a cooperation agreement with Starboard Value, averting a proxy fight with the activist investment firm.
Kenvue on Wednesday said it has added three new board members, including Starboard chief Jeffrey Smith, who has expressed disappointment with the consumer health company's management and share-price performance.
Smith last year said that Kenvue, the maker of Band-Aids and Tylenol that was spun out from Johnson & Johnson in 2023, should drill down on fixing its underperforming skin health and beauty segment and on improving the company's marketing strategy.
Starboard last month nominated a slate of four director candidates, including Smith, in a bid to reconstitute Kenvue's board.
Kenvue said it added Smith, along with independent directors Sarah Hofstetter and Erica Mann, to its board, and that Starboard will withdraw its nominees and vote its shares in favor of the Skillman, N.J., company's board slate at this year's annual meeting. Hofstetter is president of e-commerce insights platform Profitero, while Mann is a former head of Bayer's consumer-health division.
Kenvue said its board will temporarily expand to 14 directors from 11 before being reduced to 13 directors at the annual meeting.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 05, 2025 08:45 ET (13:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.